āĻšā§āĻŽICPT âĸ BMV
add
Intercept Pharmaceuticals Ord Shs
ā§Ļ.ā§Ļā§Ļ$
ā§§ā§Ž āĻ
āĻā§āĻā§, ā§¨:ā§¨ā§¨:ā§Ģā§Ļ PM GMT -ā§Ŧ · MXN · BMV · āĻĄāĻŋāĻ¸āĻā§āĻ˛ā§āĻŽāĻžāĻ°
āĻāĻžāĻ˛ āĻļā§āĻˇ āĻ¯ā§ āĻĻāĻžāĻŽā§ āĻāĻŋāĻ˛
ā§Šā§¨ā§¯.ā§Ļā§Ļ$
āĻ¸āĻžāĻ°āĻž āĻŦāĻāĻ°ā§āĻ° āĻ°ā§āĻā§āĻ
ā§Šā§¨ā§¯.ā§Ļā§Ļ$ - ā§Šā§¨ā§¯.ā§Ļā§Ļ$
āĻŽāĻžāĻ°ā§āĻā§āĻ āĻā§āĻ¯āĻžāĻĒ
ā§ā§¯.ā§Ēā§Ē āĻā§ USD
P/E āĻ
āĻ¨ā§āĻĒāĻžāĻ¤
-
āĻ˛āĻā§āĻ¯āĻžāĻāĻļ āĻĒā§āĻ°āĻĻāĻžāĻ¨
-
āĻŦāĻžāĻāĻžāĻ° āĻ¸āĻāĻŦāĻžāĻĻ
āĻĢāĻžāĻāĻ¨āĻžāĻ¨ā§āĻ¸āĻŋā§āĻžāĻ˛ āĻĒāĻžāĻ°āĻĢāĻ°ā§āĻŽā§āĻ¯āĻžāĻ¨ā§āĻ¸
āĻā§ā§āĻ° āĻ¸ā§āĻā§āĻāĻŽā§āĻ¨ā§āĻ
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ
(USD) | āĻ¸ā§āĻĒ ā§¨ā§Ļā§¨ā§Šinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
---|---|---|
āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | ā§Ž.ā§Žā§ŽÂ āĻā§ | ā§§ā§Ē.ā§Ēā§Ē% |
āĻŦā§āĻ¯āĻŦāĻ¸āĻž āĻāĻžāĻ˛āĻžāĻ¨ā§āĻ° āĻāĻ°āĻ | ā§Ž.ā§ā§Ļ āĻā§ | -ā§Ļ.ā§Ēā§§% |
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | -ā§¨ā§.ā§¯ā§Ļ āĻ˛āĻž | -ā§§ā§Ļā§§.ā§Ļā§Ē% |
āĻ¨ā§āĻ āĻĒā§āĻ°āĻĢāĻŋāĻ āĻŽāĻžāĻ°ā§āĻāĻŋāĻ¨ | -ā§Š.ā§§ā§Ē | -ā§§ā§Ļā§Ļ.ā§¯ā§§% |
āĻļā§ā§āĻžāĻ° āĻĒā§āĻ°āĻ¤āĻŋ āĻāĻĒāĻžāĻ°ā§āĻāĻ¨ | ā§Ļ.ā§Ļā§Ž | -ā§¯ā§¯.ā§¨ā§Ļ% |
EBITDA | ā§§ā§.ā§Šā§ŽÂ āĻ˛āĻž | ā§§ā§§ā§.ā§¨ā§% |
āĻĒā§āĻ°āĻ¯ā§āĻā§āĻ¯ āĻā§āĻ¯āĻžāĻā§āĻ¸ā§āĻ° āĻšāĻžāĻ° | â | â |
āĻŦā§āĻ¯āĻžāĻ˛ā§āĻ¨ā§āĻ¸ āĻļāĻŋāĻ
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ
āĻŽā§āĻ āĻĻāĻžā§
(USD) | āĻ¸ā§āĻĒ ā§¨ā§Ļā§¨ā§Šinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
---|---|---|
āĻā§āĻ¯āĻžāĻļ āĻ āĻāĻŽ āĻ¸āĻŽā§ā§āĻ° āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ | ā§Šā§¨.ā§¨ā§Â āĻā§ | -ā§Šā§Ē.ā§¨ā§Ģ% |
āĻŽā§āĻ āĻ¸āĻŽā§āĻĒāĻĻ | ā§Šā§¯.ā§Šā§¨Â āĻā§ | -ā§¨ā§¯.ā§ā§¨% |
āĻŽā§āĻ āĻĻāĻžā§ | ā§Šā§¨.ā§§ā§ŠÂ āĻā§ | -ā§¨ā§Ž.ā§Žā§% |
āĻŽā§āĻ āĻāĻā§āĻāĻāĻŋ | ā§.ā§§ā§ŽÂ āĻā§ | â |
āĻāĻāĻāĻ¸ā§āĻā§āĻ¯āĻžāĻ¨ā§āĻĄāĻŋāĻ āĻļā§ā§āĻžāĻ° | ā§Ē.ā§§ā§ŽÂ āĻā§ | â |
āĻĒā§āĻ°āĻžāĻāĻ¸ āĻā§ āĻŦā§āĻ āĻ°ā§āĻļāĻŋāĻ | ā§§ā§¯ā§§.ā§¨ā§Ž | â |
āĻ¸āĻŽā§āĻĒāĻĻ āĻĨā§āĻā§ āĻā§ | ā§Ļ.ā§¯ā§Š% | â |
āĻŽā§āĻ˛āĻ§āĻ¨ āĻĨā§āĻā§ āĻā§ | ā§§.ā§§ā§Ž% | â |
āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨
(USD) | āĻ¸ā§āĻĒ ā§¨ā§Ļā§¨ā§Šinfo | Y/Y āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ |
---|---|---|
āĻ¨ā§āĻ āĻāĻ¨āĻāĻžāĻŽ | -ā§¨ā§.ā§¯ā§Ļ āĻ˛āĻž | -ā§§ā§Ļā§§.ā§Ļā§Ē% |
āĻ
āĻĒāĻžāĻ°ā§āĻļāĻ¨ āĻĨā§āĻā§ āĻĒāĻžāĻā§āĻž āĻā§āĻ¯āĻžāĻļ | ā§§.ā§Ŧā§Â āĻā§ | ā§¨ā§Ļā§Ļ.ā§Ģā§¯% |
āĻŦāĻŋāĻ¨āĻŋā§ā§āĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | ā§Ģ.ā§¯ā§ŽÂ āĻā§ | -ā§Žā§§.ā§¯ā§% |
āĻĢāĻžāĻāĻ¨ā§āĻ¯āĻžāĻ¨ā§āĻ¸āĻŋāĻ āĻĨā§āĻā§ āĻĒā§āĻ°āĻžāĻĒā§āĻ¤ āĻā§āĻ¯āĻžāĻļ | -ā§§ā§§.ā§Ļā§Ļ āĻā§ | ā§Ģā§.ā§¨ā§% |
āĻ¨āĻāĻĻā§ āĻŽā§āĻ āĻĒāĻ°āĻŋāĻŦāĻ°ā§āĻ¤āĻ¨ | -ā§Š.ā§Šā§Â āĻā§ | -ā§§ā§Ŧā§Š.ā§Šā§¯% |
āĻĢā§āĻ°āĻŋ āĻā§āĻ¯āĻžāĻļ āĻĢā§āĻ˛ā§ | ā§§.ā§Ŧā§Â āĻā§ | ā§¨ā§§ā§§.ā§¨ā§Š% |
āĻ¸āĻŽā§āĻĒāĻ°ā§āĻā§
Intercept Pharmaceuticals, Inc. is an American biopharmaceutical company incorporated in 2002, focusing on the development of novel synthetic bile acid analogs to treat chronic liver diseases, such as primary biliary cirrhosis now called primary biliary cholangitis, non-alcoholic fatty liver disease, cirrhosis, portal hypertension, primary sclerosing cholangitis and also the intestinal disorder, bile acid diarrhea. Wikipedia
āĻ¸āĻŋāĻāĻ
āĻ¸ā§āĻĨāĻžāĻĒāĻŋāĻ¤ āĻšā§ā§āĻā§
ā§¨ā§Ļā§Ļā§¨
āĻā§ā§āĻŦāĻ¸āĻžāĻāĻ
āĻāĻ°ā§āĻŽāĻāĻžāĻ°ā§
ā§Šā§Ēā§§